KaliVir Immunotherapeutics Appoints Schond Greenway as Chief Financial Officer
DURECT Second Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
Express News | DURECT Corp - Files for Mixed Shelf Offering of up to $250 Mln- SEC Filing
Durect | 10-Q: Q2 2024 Earnings Report
Analysts Offer Insights on Healthcare Companies: Mineralys Therapeutics, Inc. (MLYS), Durect (DRRX) and Globus Medical (GMED)
Earnings Call Summary | Durect(DRRX.US) Q2 2024 Earnings Conference
DURECT Corporation (DRRX) Q2 2024 Earnings Call Transcript
Durect Seeking to Initiate Larsucosterol Phase 3 Trial in 2024 With Topline Results Expected in 2H 2026 >DRRX
Durect: Q2 Earnings Snapshot
Durect Q2 2024 GAAP EPS $(0.12) Beats $(0.17) Estimate, Sales $2.171M Miss $2.492M Estimate
Earnings Flash (DRRX) DURECT CORPORATION Posts Q2 Revenue $2.2M, Vs. Street Est of $2.49M
Express News | DURECT Q2 Net Income USD -3.7 Million
Express News | DURECT Q2 Income From Operations USD -3.404 Million
Express News | DURECT Q2 Operating Expenses USD 5.575 Million
Express News | DURECT Corporation Reports Second Quarter 2024 Financial Results and Business Update
Durect 2Q Rev $2.17M >DRRX
Durect 2Q Loss $3.7M >DRRX
Here's the Major Earnings After the Close Today
DURECT Q2 2024 Earnings Preview
Express News | DURECT Corporation to Announce Second Quarter 2024 Financial Results and Provide a Business Update